The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus.
Diabetes Res Clin Pract
; 178: 108977, 2021 Aug.
Article
in English
| MEDLINE | ID: covidwho-1322066
ABSTRACT
AIM:
COVID-19 has spread globally with heavy impact on most countries and our therapeutic strategies in COVID-19 patients with diabetes are still limited. Recently, some new information was added to this field. We performed this updated meta-analysis to reveal the underlying effect of metformin on COVID-19 patients with diabetes.METHODS:
We searched the PubMed, Embase and CNKI (China National Knowledge Infrastructure) databases for all articles. The odds ratio (OR) corresponding to the 95% confidence interval (95% CI) was used to assess the effect of metformin on COVID-19 patients with diabetes. The statistical heterogeneity among studies was assessed with the Q-test and I2 statistics.RESULTS:
We collected 17 studies including 20,719 COVID-19 patients with diabetes. Our results found that metformin was associated with significantly decreased mortality and severity in COVID-19 patients with diabetes (ORâ¯=â¯0.64, 95% CIâ¯=â¯0.51-0.79 for mortality, and ORâ¯=â¯0.81, 95% CIâ¯=â¯0.66-0.99 for severity).CONCLUSIONS:
Our meta-analysis indicated that following metformin treatment might benefit the patients with T2DM, both the mortality and severity. However, patients with severe COVID-19 should be monitored closely for the development of lactic acidosis, acidosis, and decreased kidney function.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 2
/
COVID-19
/
Hypoglycemic Agents
/
Metformin
Type of study:
Experimental Studies
/
Prognostic study
/
Reviews
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Diabetes Res Clin Pract
Journal subject:
Endocrinology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS